Response to Comments: Off-label Use of Rituximab and Rituximab Biosimilars

This response to comments indicates that no comments were received regarding the proposed LCD on off-label use of rituximab and rituximab biosimilars. The official notice period began on September 15, 2022, and the final LCD determination became effective for services on or after November 1, 2022.

"No public or provider comments were received for the proposed LCD 'Off-label Use of Rituximab and Rituximab Biosimilars'."

Sign up to see full coverage criteria, indications, and limitations.